In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Astellas licenses Asian rights to XenoPort's XP13512

Executive Summary

In its first drug development collaboration, XenoPort (improves existing therapeutics) licensed Japanese company Astellas Pharma (Yamanouchi/Fujisawa merger) exclusive rights to develop and commercialize its gabapentin prodrug XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register